Access comprehensive financial analyses and make smarter investments - get the Manual of Investments on Amazon!

Global Medical REIT (GMRE) Completes Reverse Stock Split

Global Medical REIT Inc. (NYSE: GMRE) has completed a one-for-five reverse stock split, effective as of September 19, 2025. As a result, the company's authorized shares of common stock have been reduced from 500,000,000 to 100,000,000, and the number of outstanding shares of common stock has decreased from 67,037,048 to approximately 13,407,409.

Furthermore, the reverse stock split has led to a proportionate adjustment in several key areas: The aggregate number of shares authorized for repurchase under the company's stock repurchase program has been adjusted. The aggregate number of shares issuable under the company's equity incentive plan has also been adjusted. The outstanding equity awards granted under the company's equity incentive plan have been ratably adjusted. The outstanding partnership units of Global Medical REIT L.P., the company's operating partnership, have been adjusted to reflect the reverse stock split.

It's important to note that no fractional shares were issued as a result of the reverse stock split. Instead, stockholders who would have held fractional shares are entitled to receive cash in lieu of such fractional shares, based on the closing price of Global Medical REIT Inc.'s common stock on the NYSE.

Following the reverse stock split, the company's common stock will begin trading on a reverse split-adjusted basis on the NYSE on September 22, 2025, under the symbol "GMRE" with a new CUSIP number: 37954A303.

Global Medical REIT Inc. is a net-lease medical REIT that acquires healthcare facilities and leases them to physician groups and regional and national healthcare systems. As a result of these announcements, the company's shares have moved -1.29% on the market, and are now trading at a price of $7.63. If you want to know more, read the company's complete 8-K report here.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.

IN FOCUS